Literature DB >> 27581088

Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma.

Tania Jain1, Amylou C Dueck2, Heidi E Kosiorek2, Brenda F Ginos2, Angela Mayo1, Craig B Reeder1, Marta Chesi1, Joseph Mikhael1, A Keith Stewart1, P Leif Bergsagel1, Rafael Fonseca1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27581088     DOI： 10.1002/ajh.24548

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

1.  Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients.

Authors:  T K Bera; Y Abe; T Ise; A Oberle; D Gallardo; X-F Liu; S Nagata; M Binder; I Pastan
Journal:  Leukemia       Date:  2017-11-17       Impact factor: 11.528

2.  Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis.

Authors:  Niels van Nieuwenhuijzen; Rowan Frunt; Anne M May; Monique C Minnema
Journal:  Blood Cancer J       Date:  2021-03-01       Impact factor: 11.037

Review 3.  Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.

Authors:  Tapan K Bera
Journal:  Biomolecules       Date:  2020-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.